Moderna expects to produce between 500 and 1 billion doses of its covid-19 mRNA-1273 vaccine, which the company says has shown positive results in the first phase of clinical trials.
Moderna assured this Wednesday that once they pass the three phases of clinical tests and obtain regulatory approval, they will be able to produce doses from their partner laboratories in the US and Spain to supply the main global markets.
Moderna’s CEO Talked.
Moderna CEO, Stephane Bancel, assured that the priority will be to have “capacity first in the United States”, with some 500 million doses destined for this country, which has supported the pharmaceutical company with nearly 500 million dollars.
In Europe, Moderna has partnered with the Spanish Rovi for the final phase of production of its vaccine. Its distribution model will start in Europe and continue with the rest of the world.
What Does The Data Say?
Data from the Phase 1 vaccine tests, published Tuesday in the New England Journal of Medicine, show higher levels of antibodies to the SARS-CoV-2 virus than antibodies found in people who have overcome the disease and immune response within 15 days to have a drop in those levels from day 43 on.
“It is true that, as with many other vaccines, the level of antibodies seems to decline over time,” said Tal Zaks, chief scientist at Moderna. It could indicate the need for regular vaccination.
Another of the conclusions that have derived from this first phase of tests with 45 patients is that the dose of 100 micrograms seems to be almost as effective as that of 250 micrograms.
Dosages of 50 micrograms are also being tested to clarify doubts about the amount of vaccine. These tests correspond to phase 2, in operation since May.
What’s Next To Have The Vaccine Ready?
The phase 3 and final to know if Moderna’s vaccine will obtain approval to be distributed will begin on July 27 with 30,000 volunteers chosen at random, but linked to regions where the new coronavirus has hit hardest.
The main objective of the vaccine is to protect against a symptomatic manifestation of covid-19, said Moderna today, who believes that its product will be able to protect against the main variants of SARS-CoV-2.